Skip to content
FIND A HEALTH VALLEY ACTOR

ObsEva plans job cuts

Obseva

The ObsEva laboratory is to engage in a vast restructuring process in the face of difficulties encountered with the FDA with its drug in development Linzagolix. Job cuts might be on the agenda.   The US Drug Administration (FDA) agreed in November 2021 to review the application for the drug to treat heavy periods associated with…

Read More

Nestlé Health Science invests EUR 40 million in Enterome

Nestlé - Enterome

Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases   Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…

Read More

Nestlé Health Science and Perseo Pharma partners to fight digestive diseases

Nestlé & Perseo Pharma

Strategic collaboration to create therapies against digestive diseases   Perseo pharma, a preclinical stage biopharmaceutical company focused on breaking new ground in enzyme therapies, has entered a strategic research and development collaboration with Nestlé Health Science S.A. to develop up to three programs targeting enzyme deficiencies in patients suffering from digestive diseases. “We are incredibly…

Read More

KBI Biopharma SA and Selexis SA inaugurated a new facility in Geneva

Selexis - kbi

KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, have inaugurated an expanded, fully-integrated mammalian contract development and manufacturing services facility in Plan-les-Ouates in Geneva, Switzerland. The ~8 700 m2 integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell…

Read More

Vaud invests CHF 178 Million in Life Sciences

Vaud Investments Life Sciences

To strengthen the development of the Canton and in particular the expertise of the CHUV and the University of Lausanne in Life Sciences, the State Council is requesting five investment credits totaling CHF 178.71 million from the Grand Council.   In Dorigny, these investments would allow the construction of a life sciences building and, in…

Read More

Geneva researcher wins European Inventor’s Award

Madiha Derouazi (right) and Elodie Belnoue (left)

Geneva-based researcher Madiha Derouazi is co-winner of the European Inventor Award. With the French immunologist Elodie Belnoue, she is rewarded for her therapeutic vaccines against cancer.   The European Patent Office (EPO) awarded the two researchers the European Inventor Award 2022 in the “SME” category at a ceremony in Munich on Tuesday. The teammates have…

Read More

ten23health is building a new facility in Visp

ten23health

The company plans to establish a new 5,000 m2 manufacturing facility in Visp.    In October 2021, ten23 health acquired a former Swissfillon site to install its production facility. In March 2022, a first 1,000 m2 expansion was announced. The new 5,000 m2 facility will include sterile manufacturing lines plus laboratories, offices and technical areas across…

Read More

Limula wins a prestigious EIC grant of €4.7 million

By combining its novel bioreactor with state-of-the-art sensors and predictive data intelligence, Limula will add significant value to its cell & gene therapy manufacturing solution, paving the way for in-process control for the production of highly personalised cancer treatments.

Read More

BioAlps at OM Pharma

BioAlps OM Pharma 4à6

On 9 June 2022, during a BioAlps’ 4à6 event, the Heath Valley Community had the opportunity to visit OM Pharma in Geneva.   OM Pharma is a leader in the prevention of recurrent respiratory and urinary tract infections with products regulating the immune system based on oral bacterial extracts. Broncho-Vaxom® and Uro Vaxom® are marketed…

Read More

Cytiva opens a new production site in Grens (VD)

Cityva 3D

Cytiva opens its new 7,400 m2 production facility in Grens, Switzerland, on 31 May 2022.   The site will manufacture single-use kits for the Sepax and Sefia cell processing systems, as well as consumables for the Xuri cell expansion systems. The new site will be home to 250 employees and house the Centre of Excellence…

Read More